Modified antibodies and methods for producing same

Abstract

The present invention relates to an improved modified antibody that has increased solubility and can be concentrated at a high concentration, and a method for producing the same, and to a modified antibody in which amino acids located in the framework region of the antibody have been substituted, and a method for producing the same.

Description

[Technical field]

[0001] The present invention relates to an improved modified antibody having increased solubility and capable of being concentrated at a high concentration, and a method for producing the same, and to a modified antibody in which amino acids located in the framework region of the antibody are substituted, and a method for producing the same. [Background technology]

[0002] Antibodies are used as highly effective therapeutic agents to treat diseases such as cancer, autoimmune diseases, etc. The developability of an antibody is evaluated taking into consideration high yield, stable formulation, high physicochemical and in vivo stability, high solubility, PK properties, etc.

[0003] Antibodies are protein pharmaceuticals that may be chemically unstable due to changes in covalent bonds, etc., or physically unstable due to deformation of three-dimensional spatial structure, etc. Antibodies may be chemically destabilized by hydrolysis, oxidation, deamidation, disulfide deformation, racemization, etc., and may be physically unstable due to aggregation, adsorption, dissolution, etc.

[0004] Such antibody instability can affect solubility, efficacy, etc., and reducing the stability and solubility of antibodies not only leads to reduced productivity and reduced production yields, but also increases the tendency for aggregation and increases the risk of immunogenicity.

[0005] Under such technical background, the inventors of the present application have endeavored to develop a modified antibody (also called an altered antibody or modified antibody) that can improve the solubility of the antibody and can be concentrated at a high concentration. As a result, they have confirmed that the antibody shows improved solubility through amino acid substitution at a specific position and can be concentrated at a high concentration, thereby completing the present invention. [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Next generation antibody drugs: pursuit of the 'high-hanging fruit', Nat.Rev.Drug Discovery., 2018.17:197-223. Summary of the Invention [Problem to be solved by the invention]

[0007] An object of the present invention is to provide modified antibodies or fragments thereof having improved antibody properties.

[0008] It is another object of the present invention to provide a method for producing said modified antibody or fragment thereof. [Means for solving the problem]

[0009] To achieve the above objective, the present invention provides a modified antibody or fragment thereof in which one or more amino acids selected from the group consisting of positions 13 and 42 (according to AHO numbering) in the heavy chain variable region, and position 94 (according to AHO numbering) in the light chain variable region are substituted.

[0010] The present invention also provides a method for producing a modified antibody or fragment thereof, which comprises substituting one or more amino acids selected from the group consisting of positions 13 and 42 (according to the AHO numbering system) in the heavy chain variable region, and position 94 (according to the AHO numbering system) in the light chain variable region. [Brief description of the drawings]

[0011] [Figure 1] FIG. 1 shows antibody structure modeling and hot spot analysis results. [Diagram 2]FIG. 1 shows the results of an expression test for antibody hotspots L11T, V13S, and V103S (according to the AHO numbering system; hereinafter, designated L11T, V12S, and V93S). [Diagram 3] FIG. 1 shows the results of expression tests for antibody hotspots N42T, Q77R, and N94S (according to the AHO numbering system; hereinafter, designated N35T, Q61R, and N76S). [Figure 4] FIG. 1 shows the results of expression tests for V13S, N42T, and N94S (according to the AHO numbering system; hereinafter, designated V12S, N35T, and N76S) among the antibody hotspots. [Figure 5a] FIG. 1 shows the results of antibody purification through SDS-PAGE. [Figure 5b] FIG. 1 shows the results of antibody purification through SDS-PAGE. [Figure 5c] FIG. 1 shows the results of antibody purification through SDS-PAGE. [Figure 5d] FIG. 1 shows the results of antibody purification through SDS-PAGE. [Figure 5e] FIG. 1 shows the results of antibody purification through SDS-PAGE. [Figure 5f] FIG. 1 shows the results of antibody purification through SDS-PAGE. [Figure 5g] FIG. 1 shows the results of antibody purification through SDS-PAGE. [Figure 6] FIG. 1 shows the results of a thermal stability analysis of the anti-Ang2 antibody according to the present invention. [Figure 7a] FIG. 1 shows the results of evaluating the anti-angiogenic efficacy of the anti-Ang2 antibody according to the present invention using a mouse CNV (choroidal neovascularization) model. [Figure 7b] FIG. 1 shows the results of evaluating the anti-angiogenic efficacy of the anti-Ang2 antibody according to the present invention using a mouse CNV (choroidal neovascularization) model. [Figure 7c]FIG. 1 shows the results of evaluating the anti-angiogenic efficacy of the anti-Ang2 antibody according to the present invention using a mouse CNV (choroidal neovascularization) model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, the nomenclature used herein is one that is well known and commonly used in the art.

[0013] The inventors of the present application have confirmed that when one or more amino acids selected from the group consisting of positions 13 (V12) and 42 (N35) according to the AHO numbering system in the heavy chain variable region, and position 94 (N76) according to the AHO numbering system in the light chain variable region are substituted, the antibody exhibits improved solubility, can be concentrated at high concentrations, and has improved productivity.

[0014] In particular, it was confirmed that when position 13 (V12) is substituted with serine (S) and position 42 (N35) is substituted with threonine (T) according to the AHO numbering in the heavy chain variable region, or when position 94 (N76) is substituted with serine (S) according to the AHO numbering in the light chain variable region, the antibody exhibits improved solubility, can be concentrated at high concentrations, and improves productivity.

[0015] Based on this, in one aspect, the present invention relates to a modified antibody or fragment thereof in which one or more amino acids selected from the group consisting of positions 13, 42 (according to the AHO numbering) in the heavy chain variable region, and position 94 (according to the AHO numbering) in the light chain variable region have been substituted.

[0016] The present invention also relates to a method for producing a modified antibody or a fragment thereof, which comprises substituting one or more amino acids selected from the group consisting of positions 13 and 42 (according to the AHO numbering) in the heavy chain variable region, and position 94 (according to the AHO numbering) in the light chain variable region.

[0017] The amino acid positions for the antibodies or fragments thereof disclosed in the present invention may be defined or identified by the AHO numbering system. In some cases, the amino acid positions for the antibodies or fragments thereof disclosed in the present invention may refer to sequentially numbered positions starting with the amino acid 1 at the N-terminus of the amino acid sequence of the heavy chain variable region of SEQ ID NO: 34 and the light chain variable region of SEQ ID NO: 32.

[0018] In one embodiment, positions 13 and 42 (according to the AHO numbering system) of the heavy chain variable region and position 94 (according to the AHO numbering system) of the light chain variable region may be substituted with serine (S) or threonine (T).

[0019] In specific embodiments, the amino acid substitutions may be at one or more positions selected from the group consisting of (according to the AHO numbering system):

[0020] Substitution of valine (V) at position 13 in the heavy chain variable region with serine (S);

[0021] A substitution of asparagine (N) at position 42 of the heavy chain variable region with threonine (T); and

[0022] Asparagine (N) at position 94 in the light chain variable region was replaced with serine (S).

[0023] According to specific embodiments of the invention, amino acid substitutions can be included at the following positions (according to the AHO numbering):

[0024] Substitution of valine (V) at position 13 in the heavy chain variable region with serine (S);

[0025] Substitution of asparagine (N) at position 42 in the heavy chain variable region with threonine (T);

[0026] Substitution of asparagine (N) at position 94 in the light chain variable region with serine (S);

[0027] A substitution of valine (V) at position 13 in the heavy chain variable region with serine (S), and a substitution of asparagine (N) at position 42 in the heavy chain variable region with threonine (T);

[0028] A substitution of valine (V) at position 13 in the heavy chain variable region with serine (S), and a substitution of asparagine (N) at position 94 in the light chain variable region with serine (S);

[0029] a substitution of asparagine (N) at position 42 in the heavy chain variable region with threonine (T) and a substitution of asparagine (N) at position 94 in the light chain variable region with serine (S); or

[0030] The valine (V) at position 13 in the heavy chain variable region is replaced with serine (S), the asparagine (N) at position 42 in the heavy chain variable region is replaced with threonine (T), and the asparagine (N) at position 94 in the light chain variable region is replaced with serine (S).

[0031] It was confirmed that the above-mentioned amino acid substitutions improved the solubility of the antibody, enabling it to be concentrated to a high concentration, thereby improving productivity.

[0032] Unlike the above amino acid substitutions, the desired improvement in solubility could not be confirmed when leucine at position 11 (according to the AHO numbering) in the heavy chain variable region was replaced with threonine, valine at position 103 (according to the AHO numbering) in the heavy chain variable region was replaced with serine, or glutamine at position 77 (according to the AHO numbering) in the light chain variable region was replaced with arginine.

[0033] In a specific embodiment, the modified antibody or fragment thereof of the present invention may comprise one or more scaffold regions selected from the group consisting of:

[0034] QVQLVESGGGLX1KPGGSLRLSCAAS (where X1 is S);

[0035] MX2WVRQAPGKGLEWVSS (where X2 is T); and

[0036] NLQSGVSSQFSGSGSGTDFTLTIX3SLQPEDSATYYC (the above X3 is S).

[0037] Specifically, for O4, an anti-Ang2 antibody clone comprising a heavy chain variable region of SEQ ID NO: 34 and a light chain variable region of SEQ ID NO: 32, one or more amino acids selected from the group consisting of positions 12, 35, and 76 of the heavy chain variable region can be substituted with serine (S) or threonine (T).

[0038] In one embodiment, O4, an anti-Ang2 antibody clone comprising a heavy chain variable region of SEQ ID NO: 34 and a light chain variable region of SEQ ID NO: 32, may contain one or more amino acid substitutions selected from the group consisting of the following:

[0039] Substitution of valine (V) at position 12 in the heavy chain variable region with serine (S);

[0040] A substitution of asparagine (N) at position 35 of the heavy chain variable region with threonine (T); and

[0041] Asparagine (N) at position 76 in the light chain variable region was replaced with serine (S).

[0042] Specifically, according to the present invention, the following amino acid substitutions may be included:

[0043] Substitution of valine (V) at position 12 in the heavy chain variable region with serine (S);

[0044] Substitution of asparagine (N) at position 35 of the heavy chain variable region with threonine (T);

[0045] Substitution of asparagine (N) at position 76 in the light chain variable region with serine (S);

[0046] A substitution of valine (V) at position 12 in the heavy chain variable region with serine (S), and a substitution of asparagine (N) at position 35 in the heavy chain variable region with threonine (T);

[0047] A substitution of valine (V) at position 12 in the heavy chain variable region with serine (S), and a substitution of asparagine (N) at position 76 in the light chain variable region with serine (S);

[0048] a substitution of asparagine (N) at position 35 in the heavy chain variable region with threonine (T) and asparagine (N) at position 76 in the light chain variable region with serine (S); or

[0049] The valine (V) at position 12 in the heavy chain variable region is replaced with serine (S), the asparagine (N) at position 35 in the heavy chain variable region is replaced with threonine (T), and the asparagine (N) at position 76 in the light chain variable region is replaced with serine (S).

[0050] As a result of improving the physical properties of O4, an anti-Ang2 antibody clone comprising a heavy chain variable region of SEQ ID NO: 34 and a light chain variable region of SEQ ID NO: 32, it was confirmed that when FR1 of the heavy chain variable region contains a framework region having the sequence of QVQLVESGGGLX1KPGGSLRLSCAAS (X1 is S), FR3 contains a framework region having the sequence of MX2WVRQAPGKGLEWVSS (X2 is T), or FR1 contains a framework region having the sequences of QVQLVESGGGLX1KPGGSLRLSCAAS (X1 is S) and FR3 contains a framework region having the sequences of MX2WVRQAPGKGLEWVSS (X2 is T), the solubility of the antibody is improved and it can be concentrated at a high concentration, thereby improving productivity.

[0051] In addition, it was confirmed that when FR3 of the light chain variable region contains a framework region having the sequence NLQSGVSSQFSGSGSGTDFTLTIX3SLQPEDSATYYC (X3 is S), the solubility of the antibody is improved and it can be concentrated at a high concentration, thereby improving productivity.

[0052] Further, the heavy chain variable region includes a framework region having a sequence of QVQLVESGGGLX1KPGGSLRLSCAAS (X1 is S) in FR1, and a light chain variable region includes a framework region having a sequence of NLQSGVSSQFSGSGSGTDFTLTIX3SLQPEDSATYYC (X3 is S) in FR3;

[0053] The heavy chain variable region FR3 comprises a framework region having the sequence MX2WVRQAPGKGLEWVSS (wherein X2 is T), and the light chain variable region FR3 comprises a framework region having the sequence NLQSGVSSQFSGSGSGTDFTLTIX3SLQPEDSATYYC (wherein X3 is S), or

[0054] It was confirmed that when FR1 of the heavy chain variable region contains a framework region having the sequence QVQLVESGGGLX1KPGGSLRLSCAAS (the X1 is S), FR3 of the heavy chain variable region contains a framework region having the sequence MX2WVRQAPGKGLEWVSS (the X2 is T), and FR3 of the light chain variable region contains a framework region having the sequence NLQSGVSSQFSGSGSGTDFTLTIX3SLQPEDSATYYC (the X3 is S), the solubility of the antibody is improved and it can be concentrated at a high concentration, thereby improving productivity.

[0055] Optionally, the modified antibody or fragment thereof of the present invention can be an antibody or antigen-binding fragment thereof that binds to Ang2 (Angiopoietin-2).

[0056] In this case, the antibody or antigen-binding fragment thereof is

[0057] A heavy chain CDR1 selected from the group consisting of SEQ ID NOs: 1, 7, 13, 19 and 25;

[0058] A heavy chain CDR2 selected from the group consisting of SEQ ID NOs: 2, 8, 14, 20 and 26, and

[0059] A heavy chain variable region comprising a heavy chain CDR3 selected from the group consisting of SEQ ID NOs: 3, 9, 15, 21, 27, 43, 44, and 45; and

[0060] A light chain CDR1 selected from the group consisting of SEQ ID NOs: 4, 10, 16, 22, and 28;

[0061] a light chain CDR2 selected from the group consisting of SEQ ID NOs: 5, 11, 17, 23 and 29; and

[0062] The antibody may comprise a light chain variable region comprising a light chain CDR3 selected from the group consisting of SEQ ID NOs: 6, 12, 18, 24 and 30.

[0063] TIFF0007669062000001.tif204170TIFF0007669062000002.tif176170

[0064] The term "antibody" as used herein refers to an anti-Ang2 antibody that specifically binds to Ang2. The scope of the present invention includes not only intact antibody forms that specifically bind to Ang2, but also antigen-binding fragments of the antibody molecule.

[0065] Intact antibodies have a structure with two full-length light chains and two full-length heavy chains, with each light chain linked to a heavy chain by disulfide bonds. Heavy chain constant regions are of gamma (γ), mu (μ), alpha (α), delta (δ) and epsilon (ε) types, with gamma 1 (γ1), gamma 2 (γ2), gamma 3 (γ3), gamma 4 (γ4), alpha 1 (α1) and alpha 2 (α2) subclasses. Light chain constant regions are of kappa (κ) and lambda (λ) types.

[0066] The antigen-binding fragment of an antibody or antibody fragment means a fragment having an antigen-binding function, and includes Fab, F(ab'), F(ab')2, and Fv. Among antibody fragments, Fab has a structure having light and heavy chain variable regions, a light chain constant region, and the first constant region (CH1) of the heavy chain, and has one antigen-binding site. Fab' differs from Fab in that it has a hinge region containing one or more cysteine ​​residues at the C-terminus of the heavy chain CH1 domain. F(ab')2 antibody is produced by disulfide bonds formed between cysteine ​​residues in the hinge region of Fab'. Fv is the smallest antibody fragment having only a heavy chain variable region and a light chain variable region. In a two-chain Fv, the heavy chain variable region and the light chain variable region are linked by a non-covalent bond, and in a single-chain Fv (scFv), the heavy chain variable region and the light chain variable region are generally linked by a covalent bond via a peptide linker or directly at the C-terminus, and can form a dimer-like structure like the two-chain Fv. Such antibody fragments can be obtained using protease (for example, Fab can be obtained by restrictive cleavage of the whole antibody with papain, and F(ab')2 fragment can be obtained by cleavage with pepsin), or can be produced through gene recombination technology.

[0067] In one embodiment, the antibody of the present invention is in the form of an Fv (e.g., scFv) or in the form of a complete antibody. The heavy chain constant region can be selected from any one of the isotypes gamma (γ), mu (μ), alpha (α), delta (δ) and epsilon (ε). For example, the constant region is gamma 1 (IgG1), gamma 3 (IgG3) or gamma 4 (IgG4). The light chain constant region can be of the kappa or lambda type.

[0068] As used herein, the term "heavy chain" refers to a full-length heavy chain and fragments thereof that includes a variable region domain VH that contains an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen, and three constant region domains CH1, CH2, and CH3. As used herein, the term "light chain" refers to a full-length light chain and fragments thereof that includes a variable region domain VL that contains an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen, and a constant region domain CL.

[0069] Antibodies of the present invention include, but are not limited to, monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, single chain Fvs (scFV), single chain antibodies, Fab fragments, F(ab') fragments, disulfide-linked Fvs (sdFV) and anti-idiotypic (anti-Id) antibodies, or epitope-binding fragments of each of the above antibodies.

[0070] The term monoclonal antibody refers to an antibody obtained from a substantially homogeneous antibody population, i.e., the individual antibodies populating the population are identical except for possible naturally occurring mutations which may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. In contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.

[0071] "Epitope" refers to a protein determinant to which an antibody can specifically bind. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and generally have specific three-dimensional structural features as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.

[0072] The "humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. In most cases, humanized antibodies are human immunoglobulins (acceptor antibody) in which residues from a hypervariable region of an acceptor are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate that possesses the desired specificity, affinity, and capacity.

[0073] The "human antibody" is a molecule derived from human immunoglobulin, and means that all of the amino acid sequences constituting the antibody, including the complementarity determining regions and structural regions, are composed of human immunoglobulin.

[0074] These include "chimeric" antibodies (immunoglobulins) in which portions of the heavy and / or light chains are identical to or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while remaining chains are identical to or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies that exhibit the desired biological activity.

[0075] As used herein, "antibody variable domain" refers to the light and heavy chain portions of an antibody molecule that contain the amino acid sequences of the complementarity determining regions (CDRs; i.e., CDR1, CDR2, and CDR3) and framework regions (FRs). VH refers to the variable domain of the heavy chain. VL refers to the variable domain of the light chain.

[0076] "Complementarity determining region" (CDR; i.e., CDR1, CDR2, and CDR3) refers to the amino acid residues of an antibody variable domain that are necessary for antigen binding. Each variable domain typically has three CDR regions identified as CDR1, CDR2 and CDR3. The present invention includes a heavy chain variable region comprising a heavy chain CDR3 of SEQ ID NO:1, and a light chain variable region comprising a light chain CDR3 of SEQ ID NO:2.

[0077] In the present invention, the antibody or antigen-binding fragment thereof that binds to Ang2 comprises a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 1, a heavy chain CDR2 of SEQ ID NO: 2, and a heavy chain CDR3 of SEQ ID NO: 3; a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 4, a light chain CDR2 of SEQ ID NO: 5, and a light chain CDR3 of SEQ ID NO: 6;

[0078] a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 7, a heavy chain CDR2 of SEQ ID NO: 8, and a heavy chain CDR3 of SEQ ID NO: 9; a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 10, a light chain CDR2 of SEQ ID NO: 11, and a light chain CDR3 of SEQ ID NO: 12;

[0079] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 13, a heavy chain CDR2 of SEQ ID NO: 14, and a heavy chain CDR3 of SEQ ID NO: 15; a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 16, a light chain CDR2 of SEQ ID NO: 17, and a light chain CDR3 of SEQ ID NO: 18;

[0080] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 19, a heavy chain CDR2 of SEQ ID NO: 20, and a heavy chain CDR3 of SEQ ID NO: 21; a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 22, a light chain CDR2 of SEQ ID NO: 23, and a light chain CDR3 of SEQ ID NO: 24;

[0081] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 25, a heavy chain CDR2 of SEQ ID NO: 26, and a heavy chain CDR3 of SEQ ID NO: 27; a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 28, a light chain CDR2 of SEQ ID NO: 29, and a light chain CDR3 of SEQ ID NO: 30;

[0082] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 13, a heavy chain CDR2 of SEQ ID NO: 14, and a heavy chain CDR3 of SEQ ID NO: 43; a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 16, a light chain CDR2 of SEQ ID NO: 17, and a light chain CDR3 of SEQ ID NO: 18;

[0083] a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 13, a heavy chain CDR2 of SEQ ID NO: 14, and a heavy chain CDR3 of SEQ ID NO: 44; a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 16, a light chain CDR2 of SEQ ID NO: 17, and a light chain CDR3 of SEQ ID NO: 18; or

[0084] It may comprise a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 13, a heavy chain CDR2 of SEQ ID NO: 14, and a heavy chain CDR3 of SEQ ID NO: 45, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 16, a light chain CDR2 of SEQ ID NO: 17, and a light chain CDR3 of SEQ ID NO: 18.

[0085] "Framework regions" (FRs) are the variable domain residues other than the CDR residues. Each variable domain typically has four FRs identified as FR1, FR2, FR3 and FR4. In order to develop improved antibody productivity and highly concentrated formulations, the inventors of the present application have induced mutations in the framework regions with the goal of improving productivity and solubility.

[0086] An "Fv" fragment is an antibody fragment that contains a complete antigen recognition and binding site. Such a region consists of a dimer of one heavy- and one light-chain variable domain in a tight, substantially covalent association, e.g., scFv.

[0087] The "Fab" fragment contains the variable and constant domains of the light chain and the variable and first constant domain (CH1) of the heavy chain. F(ab')2 antibody fragments generally comprise a pair of Fab fragments covalently linked near their carboxy termini by hinge cysteines between them.

[0088] "Single-chain Fv" or "scFv" antibody fragments comprise the VH and VL domains of antibody, but these domains are present in a single polypeptide chain. The Fv polypeptide can further comprise a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding.

[0089] The antibody of the present invention is functionally -5 M to 10 -12 The binding affinity of M is within the range shown in Table 1. Despite the amino acid substitutions according to the present invention, the affinity for the antigen may be reduced or may not be negatively affected.

[0090] For example, the binding affinity of the modified antibody to the antigen is 10 -6 M to 10 -12 M, 10 -7 M to 10 -12 M, 10 -8 M to 10 -12 M, 10 -9 M to 10 -12 M, 10 -5 M to 10 -11 M, 10 -6 M to 10 -11 M, 10 -7 M to 10 -11 M, 10 -8 M to 10 -11 M, 10 -9 M to 10 -11 M, 10 -10 M to 10 -11 M, 10 -5 M to 10 -10 M, 10 -6 M to 10 -10 M, 10 -7 M to 10 -10 M, 10 -8 M to 10 -10 M, 10 -9 M to 10 -10 M, 10 -5 M to 10 -9 M, 10 -6 M to 10 -9 M, 10 -7 M to 10 -9 M, 10 -8 M to 10 -9 M, 10 -5 M to 10 -8 M, 10 -6 M to 10 -8 M, 10 -7 M to 10 -8 M, 10 -5 M to 10 -7 M, 10 -6 M to 10 -7 M or 10 -5 M to 10 -6 It's M.

[0091] Modified antibodies of the present invention can comprise a heavy chain variable region selected from the group consisting of SEQ ID NOs:31, 33, 36 and / or a light chain variable region of SEQ ID NO:35.

[0092] In a specific embodiment of the present invention, a heavy chain variable region of SEQ ID NO: 31 and a light chain variable region of SEQ ID NO: 32;

[0093] A heavy chain variable region of SEQ ID NO:33 and a light chain variable region of SEQ ID NO:32;

[0094] A heavy chain variable region of SEQ ID NO:34 and a light chain variable region of SEQ ID NO:35;

[0095] A heavy chain variable region of SEQ ID NO:36 and a light chain variable region of SEQ ID NO:32;

[0096] A heavy chain variable region of SEQ ID NO:31 and a light chain variable region of SEQ ID NO:35;

[0097] A heavy chain variable region of SEQ ID NO: 33 and a light chain variable region of SEQ ID NO: 35; or

[0098] a heavy chain variable region of SEQ ID NO:36 and a light chain variable region of SEQ ID NO:35;

[0099] The modified antibody or fragment thereof of the present invention may include not only the antibody sequences described herein, but also biological equivalents thereof, so long as the desired function is maintained. For example, additional changes may be made to the amino acid sequence of the antibody to further improve the binding affinity and / or other biological properties of the antibody. Such modifications include, for example, deletion, insertion and / or substitution of residues in the amino acid sequence of the antibody. Such amino acid mutations are based on the relative similarity of the amino acid side chain substitutes, such as hydrophobicity, hydrophilicity, charge, size, etc. Analysis of the size, shape and type of amino acid side chain substitutes reveals that arginine, lysine and histidine are all positively charged residues; alanine, glycine and serine have similar sizes; and phenylalanine, tryptophan and tyrosine have similar shapes. Thus, based on these considerations, arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine are biologically functional equivalents.

[0100] Considering the above-mentioned biologically equivalent mutations, the antibody of the present invention or the nucleic acid molecule encoding the antibody of the present invention is also understood to include sequences that show substantial identity with the sequences described in SEQ ID NO. The substantial identity means a sequence that shows at least 90% homology, most preferably at least 95% homology, 96% or more, 97% or more, 98% or more, or 99% or more homology when the above-mentioned sequence of the present invention is aligned with any other sequence to maximize its correspondence and the aligned sequences are analyzed using an algorithm commonly used in the art. Alignment methods for sequence comparison are well known in the art. NCBI BLAST (Basic Local Alignment Search Tool) is accessible at NCBI, etc., and can be used in conjunction with sequence analysis programs such as blastp, blastm, blastx, tblastn, and tblastx on the Internet. BLSAT can be accessed at www.ncbi.nlm.nih.gov / BLAST / . Methods for sequence homology comparison using this program can be found at www.ncbi.nlm.nih.gov / BLAST / blast_help.html.

[0101] On this basis, the antibodies or antigen-binding fragments thereof of the present invention can have 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homology to the sequences explicitly set forth herein or to the entirety of the sequences. Such homology can be determined by sequence comparison and / or alignment using methods known in the art. For example, percent sequence homology of the nucleic acids or proteins of the present invention can be determined using sequence comparison algorithms (i.e., BLAST or BLAST 2.0), manual alignment and visual inspection.

[0102] In another aspect, the invention relates to a nucleic acid encoding the modified antibody or fragment thereof.

[0103] Nucleic acids encoding the antibodies or antigen-binding fragments thereof of the invention can be isolated and the antibodies or antigen-binding fragments thereof can be produced in recombinant form. The nucleic acids can be isolated and inserted into a replicable vector for further cloning (amplification of the DNA) or further expression. Based on this, the invention relates in a further aspect to vectors comprising said nucleic acids.

[0104] The term "nucleic acid" refers to a nucleic acid that comprehensively includes DNA (gDNA and cDNA) and RNA molecules, and the basic building block of a nucleic acid is a nucleotide, which includes not only natural nucleotides but also analogs in which the sugar or base moiety is modified. The sequences of the nucleic acids encoding the heavy and light chain variable regions of the present invention may be modified. Such modifications include addition, deletion, non-conservative substitution, or conservative substitution of nucleotides.

[0105] In a specific embodiment of the present invention, the nucleic acid comprises:

[0106] a sequence encoding a heavy chain variable region of SEQ ID NO: 37 and a sequence encoding a light chain variable region of SEQ ID NO: 38;

[0107] a sequence encoding a heavy chain variable region of SEQ ID NO: 39 and a sequence encoding a light chain variable region of SEQ ID NO: 38;

[0108] a sequence encoding a heavy chain variable region of SEQ ID NO: 40 and a sequence encoding a light chain variable region of SEQ ID NO: 41;

[0109] a sequence encoding a heavy chain variable region of SEQ ID NO: 42 and a sequence encoding a light chain variable region of SEQ ID NO: 38;

[0110] a sequence encoding a heavy chain variable region of SEQ ID NO: 37 and a sequence encoding a light chain variable region of SEQ ID NO: 41;

[0111] A sequence encoding a heavy chain variable region of SEQ ID NO: 39 and a sequence encoding a light chain variable region of SEQ ID NO: 41; or

[0112] a sequence encoding the heavy chain variable region of SEQ ID NO:42 and a sequence encoding the light chain variable region of SEQ ID NO:41.

[0113] The DNA encoding the antibody is readily isolated or synthesized using conventional procedures (e.g., by using oligonucleotide probes that can specifically bind to DNA encoding the heavy and light chains of the antibody). Many vectors are available. The vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.

[0114] As used herein, the term "vector" refers to a means for expressing a gene of interest in a host cell, and includes plasmid vectors, cosmid vectors, bacteriophage vectors, adenovirus vectors, retrovirus vectors, adeno-associated virus vectors, and other viral vectors. In the vector, the nucleic acid encoding the antibody is operably linked to a promoter.

[0115] "Operably linked" refers to a functional association between a nucleic acid expression control sequence (e.g., a promoter, a signal sequence, or an array of transcription factor binding sites) and another nucleic acid sequence, such that the control sequence controls the transcription and / or translation of the other nucleic acid sequence.

[0116] When a prokaryotic cell is used as the host, it generally contains a strong promoter capable of proceeding transcription (e.g., tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pLλ promoter, pRλ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter, T7 promoter, etc.), a ribosome binding site for the initiation of translation, and a transcription / translation termination sequence. For example, when a eukaryotic cell is used as the host, a promoter derived from the genome of a mammalian cell (e.g., metallothionine promoter, β-actin promoter, human hemoglobin promoter, and human muscle creatine promoter) or a promoter derived from a mammalian virus (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus (CMV) promoter, HSV tk promoter, mouse mammary tumor virus (MMTV) promoter, HIV LTR promoter, Moloney virus promoter, Epstein-Barr virus (EBV) promoter, and Rous sarcoma virus (RSV) promoter) can be used, and generally has a polyadenylation sequence as a transcription termination sequence.

[0117] In some cases, the vector may be fused to other sequences to facilitate purification of the antibody expressed therefrom, such as glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA) and 6x His (hexahistidine; Qiagen, USA).

[0118] The vectors contain antibiotic resistance genes commonly used in the art as selection markers, for example, the vectors include genes for resistance to ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin, and tetracycline.

[0119] In yet another aspect, the present invention relates to a cell transformed with the above-mentioned vector. The cells used to produce the antibodies of the present invention may be, but are not limited to, prokaryotic, yeast or higher eukaryotic cells.

[0120] Prokaryotic host cells such as strains of the genus Escherichia coli, Bacillus, such as Bacillus subtilis and Bacillus thuringiensis, Streptomyces, Pseudomonas (e.g., Pseudomonas putida), Proteus mirabilis, and Staphylococcus (e.g., Staphylococcus carnosus) can be used.

[0121] However, of greatest interest are animal cells, and examples of useful host cell lines can be, but are not limited to, COS-7, BHK, CHO, CHOK1, DXB-11, DG-44, CHO / -DHFR, CV1, COS-7, HEK293, BHK, TM4, VERO, HELA, MDCK, BRL 3A, W138, Hep G2, SK-Hep, MMT, TRI, MRC 5, FS4, 3T3, RIN, A549, PC12, K562, PER.C6, SP2 / 0, NS-0, U20S, or HT1080.

[0122] In yet another aspect, the present invention relates to a method for producing a modified antibody or a fragment thereof, which comprises substituting the amino acid at position 12 or position 35 in the heavy chain variable region and / or position 76 in the light chain variable region with serine (S) or threonine (T), respectively.

[0123] The nucleic acid encoding the modified antibody or fragment thereof can be introduced into the cells. The cells can be cultured in a variety of media. Any commercially available medium can be used as the culture medium without limitation. Any other necessary supplements known to those of skill in the art can be included at appropriate concentrations. The culture conditions, e.g., temperature, pH, etc., will be those already used with the host cell selected for expression and will be apparent to those of skill in the art.

[0124] The antibody or a fragment thereof can be recovered by, for example, removing impurities by centrifugation or ultrafiltration, and purifying the resultant using, for example, affinity chromatography, etc. Additional purification techniques, for example, anion or cation exchange chromatography, hydrophobic interaction chromatography, hydroxyapatite chromatography, etc., can be used.

[0125] In yet another aspect, the present invention relates to a composition for preventing or treating a tumor, comprising the antibody or a fragment thereof as an active ingredient. The antibody may be an IgG or a fragment containing the variable region, i.e., ScFv or Fab. The variable region of the heavy chain may be IgG1, IgG2, IgG3, or IgG4.

[0126] The present invention may be, for example, a pharmaceutical composition for preventing or treating an eye disease, comprising: (a) a pharma- ceutical effective amount of the antibody or fragment thereof according to the present invention; and (b) a pharma- ceutical acceptable carrier. The present invention may also be a method for preventing or treating an eye disease, comprising administering the antibody or antigen-binding fragment thereof to a patient with an eye disease. Furthermore, the present invention may be a use of the antibody or antigen-binding fragment thereof to interfere with the mechanism of Ang2, and thereby to prevent or treat an eye disease.

[0127] In relation to eye diseases, the cornea is an avascular tissue and must maintain transparency at all times to preserve vision. However, the generation of new blood vessels also occurs in the eye, and is known to induce diseases related to the neovascularization of the eye. That is, the generation of new blood vessels in the cornea causes loss of vision by inhibiting the transparency of the eye, and the generation of new blood vessels in the retina causes abnormal blood vessels to form, which causes blood leakage and leads to blindness through the degeneration of retinal cells.

[0128] Based on this, the present invention may be used to prevent or treat ocular diseases, such as retinopathy of prematurity, corneal neovascular diseases, diabetic retinopathy, choroidal neovascular diseases, macular degeneration (e.g., age-related macular degeneration), and the like.

[0129] The present invention may be, for example, a pharmaceutical composition for preventing or treating a tumor, comprising: (a) a pharma- ceutical effective amount of the antibody or fragment thereof according to the present invention; and (b) a pharma- ceutical acceptable carrier. The present invention may also be a method for preventing or treating a tumor, comprising administering the antibody or antigen-binding fragment thereof to a tumor patient. Furthermore, the present invention may be a use of the antibody or antigen-binding fragment thereof to interfere with the mechanism of Ang2, and thereby to prevent or treat a tumor.

[0130] Tumors, which are diseases to which the composition is applied, typically include tumors or cancers that overexpress Ang2, and tumors or cancers that do not overexpress Ang2. Non-limiting examples of tumors or cancers that are preferred for treatment include melanoma (e.g., metastatic malignant melanoma), kidney cancer (e.g., clear cell carcinoma), prostate cancer (e.g., hormone refractory prostate cancer), pancreatic adenocarcinoma, breast cancer (optionally triple-negative breast cancer), colon cancer, lung cancer (e.g., non-small cell lung cancer), esophageal cancer, head and neck squamous cell carcinoma, liver cancer, ovarian cancer, cervical cancer, thyroid cancer, glioblastoma, glioblastoma, leukemia, lymphoma, and other neoplastic cancers. Furthermore, the present invention includes refractory or recurrent cancers that can be treated using the antibody of the present invention.

[0131] In yet another aspect, the present invention relates to a pharmaceutical composition for inhibiting angiogenesis, comprising the antibody or a fragment thereof as an active ingredient. Yet another example provides a pharmaceutical composition for preventing and / or treating diseases associated with Ang2 activation and / or overproduction, comprising the antibody or a fragment thereof as an active ingredient.

[0132] In the present invention, for example, there is provided a method for inhibiting angiogenesis, comprising the step of administering a therapeutically effective amount of the antibody or a fragment thereof to a patient in need of angiogenesis inhibition. The method for inhibiting angiogenesis may further comprise the step of identifying a patient in need of angiogenesis inhibition prior to the administering step. In yet another example, there is provided a method for preventing and / or treating a disease associated with Ang2 activation and / or overproduction, comprising the step of administering a therapeutically effective amount of the antibody or a fragment thereof to a patient in need of prevention and / or treatment of a disease associated with Ang2 activation and / or overproduction. The method for preventing and / or treating may further comprise the step of identifying a patient in need of prevention and / or treatment of a disease associated with Ang2 activation and / or overproduction prior to the administering step.

[0133] The pharmaceutical composition may further include a pharma- ceutically acceptable carrier, which may be one or more selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, etc., but is not limited thereto. The pharmaceutical composition may further include one or more selected from the group consisting of diluents, excipients, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, and preservatives, which are generally used in the preparation of pharmaceutical compositions.

[0134] An effective amount of the pharmaceutical composition, the antibody or its antigen-binding fragment can be administered orally or parenterally. Parenteral administration can include intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intradermal administration, topical administration, intranasal administration, intrapulmonary administration, and intrarectal administration. Since proteins or peptides are digested during oral administration, oral compositions can be formulated to coat or protect active agents from such degradation. In addition, the compositions can be administered by any device that can transport active agents to target cells.

[0135] The content of the antibody or fragment thereof in the pharmaceutical composition may be formulated in various ways depending on factors such as the formulation method, administration method, age, weight, sex, pathological condition, food, administration time, administration interval, administration route, excretion rate, and reaction sensitivity. For example, the daily dose of the antibody or fragment thereof may be in the range of 0.001 mg / kg to 1000 mg / kg, specifically 0.01 mg / kg to 100 mg / kg, more specifically 0.1 mg / kg to 50 mg / kg, and even more specifically 0.1 mg / kg to 20 mg / kg, but is not limited thereto. The daily dose may be formulated in a single formulation in the form of a unit dose, or may be formulated in appropriate amounts, or may be prepared in a multi-capacity container.

[0136] The pharmaceutical composition may be administered in combination with other drugs, such as other angiogenesis inhibitors or therapeutic agents for diseases associated with Ang2 activation and / or overproduction, and the dosage, administration method and type of other drugs may be prescribed appropriately depending on the condition of the patient.

[0137] The pharmaceutical composition may be in the form of a solution, suspension, syrup or emulsion in an oil or aqueous medium, or may be formulated in the form of an extract, powder, granules, tablet or capsule, and may further contain a dispersant or stabilizer for formulation.

[0138] In particular, the pharmaceutical composition comprising the antibody or a fragment thereof may be formulated into an immunoliposome since it contains an antibody or an antigen-binding fragment. The liposome comprising the antibody may be prepared by a method well known in the art. The immunoliposome is a lipid composition comprising phosphatidylcholine, cholesterol and polyethylene glycol-derivatized phosphatidylethanolamine, and may be prepared by reverse phase evaporation (Korean Patent Publication No. 10-2015-0089329). For example, the Fab' fragment of the antibody may be conjugated to the liposome through a disulfide exchange reaction.

[0139] Meanwhile, since the antibody or a fragment thereof specifically binds to Ang2, the presence or absence of Ang2 activation and / or overproduction can be confirmed using the antibody or a fragment thereof. Thus, still another embodiment of the present invention provides a pharmaceutical composition for diagnosing Ang2 activation and / or overproduction and / or a disease associated with Ang2 activation and / or overproduction, comprising the antibody or an antigen-binding fragment thereof. In still another embodiment, the present invention provides a method for diagnosis or a method for providing information for diagnosis, comprising the steps of treating a biological sample obtained from a patient with the antibody or a fragment thereof; determining whether or not there is an antigen-antibody reaction; and, if an antigen-antibody reaction is detected, determining that the patient has a symptom of Ang2 activation and / or overproduction or a disease associated with Ang2 activation and / or overproduction. The biological sample may be selected from the group consisting of cells, tissues, body fluids, etc. obtained from a patient.

[0140] The step of determining whether or not the antigen-antibody reaction occurs can be carried out by various methods known in the art, for example, by a conventional enzyme reaction, fluorescence, luminescence and / or radiation detection, specifically, by a method selected from the group consisting of immunochromatography, immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), enzymeimmunoassay (EIA), fluorescence immunoassay (FIA), luminescence immunoassay (LIA), Western blotting, etc., but is not limited thereto.

[0141] The subject of administration or diagnosis of the pharmaceutical composition may be a mammal, including humans, primates including monkeys, and rodents including mice and rats.

[0142] The disease associated with Ang2 activation and / or overproduction may be cancer; cancer metastasis; eye disease such as retinopathy of prematurity, corneal neovascular disease, diabetic retinopathy, choroidal neovascular disease, macular degeneration (e.g., age-related macular degeneration); asthma; rheumatoid arthritis; psoriasis; inflammatory disease such as pneumonia, chronic inflammation; cardiovascular disease such as hypertension, arteriosclerosis, or sepsis, etc. The cancer may overexpress Ang2 or may be a solid cancer or a blood cancer. Furthermore, the cancer may be, but is not limited to, one or more selected from the group consisting of squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous cell carcinoma of the lung, peritoneal cancer, skin cancer, cutaneous or intraocular melanoma, rectal cancer, cancer near the anus, esophageal cancer, small intestinal cancer, endocrine gland cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, chronic or acute leukemia, lymphocytic lymphoma, hepatocellular carcinoma, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, liver tumor, breast cancer (optionally triple-negative breast cancer), colon cancer, large intestine cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, head and neck cancer, brain cancer, osteosarcoma, etc. The cancer may be primary cancer or metastatic cancer. EXAMPLES

[0143] The present invention will be described in more detail with reference to the following examples. It will be obvious to those skilled in the art that these examples are merely for the purpose of illustrating the present invention and are not intended to limit the scope of the present invention.

[0144] By applying anti-Ang2 antibody to eye diseases and injecting a large amount of anti-Ang2 antibody, better results are expected. Since the volume that can be injected into the eye is limited, a stable formulation with a highly concentrated condition was required in the past. In order to create a more highly concentrated formulation than the existing anti-Ang2 antibody, we succeeded in creating a highly concentrated formulation by using hot spot analysis based on the antibody structure and a formulation buffer.

[0145] Example 1. Creation of mutants to improve physical properties

[0146] The physical properties of the anti-Ang2 antibody clone O4 (containing the heavy chain variable region of SEQ ID NO: 34 and the light chain variable region of SEQ ID NO: 32) were improved.

[0147] [Table 1]

[0148] Amino acids likely to cause aggregation of anti-Ang2 antibodies were analyzed using Discovery Studio (BIOBIA) software. Leu 11, Val 12, Asn 35, and Val 93 amino acids in VH, and Gln 61 and Asn 76 amino acids in VL were analyzed as hotspots that affect physical properties (Figure 1, Table 2). The amino acids analyzed as hotspots were mutated, and mutants with improved physical properties were expressed and selected.

[0149] [Table 2]

[0150] Example 2. Creation of mutants to improve physical properties

[0151] In order to improve the physical properties of anti-Ang2 antibody (O4), amino acids selected by hotspot analysis were replaced. An expression test of the construct with the modified amino acids was performed. A clone with point mutation was amplified using PCR technique in the anti-Ang2 antibody (O4) gene. The amplified gene was inserted into an expression vector (Merck Millipore, pET 22b(+)) to complete cloning. The cloned plasmid was inserted into an expression host cell (Merck Millipore, BL21(DE3)) and transformed. For the expression test, 2XYT medium was supplemented with 100μg / ml ampicillin, and the transformed cells were inoculated and cultured at 37℃ for 8 hours. After lowering the temperature to 25℃, induction was performed by adding 0.5mM IPTG, and culture was performed for 18 hours. The cells were harvested by centrifugation at 8000rpm for 10 minutes. The precipitated cells were suspended in 50 mM Tris, 150 mM NaCl pH 7.4 buffer and disrupted by sonication. The disrupted cells were separated from the supernatant by centrifugation at 13,000 rpm for 1 hour, and expression was confirmed by SDS-PAGE (Figures 2, 3, and 4).

[0152] Example 3. Optimized anti-Ang2 antibody ScFv production

[0153] In order to express the anti-Ang2 antibody with improved physical properties in E. coli, it was cloned into pET-22b vector (Novagen). Colonies generated by transformation into BL21(DE3) were selected, and E. coli pre-cultured at 37℃ and 200 rpm in LB (Lysogeny broth) medium supplemented with 100μg / ml ampicillin was inoculated at 1% into LB medium containing 100μg / ml ampicillin antibiotic. Culture was performed at 37℃ and 200 rpm. When OD600 reached 0.6-0.8, the temperature of the incubator was lowered to 20℃, 0.5mM IPTG was added, and cultured for 16 hours.

[0154] The cultured E. coli was collected by centrifugation at 8000 rpm for 10 minutes. After removing the medium, the cells were resuspended in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM PMSF (Phenylmethylsulfonylfluoride)) at 10 ml per gram of cell weight. The cells were disrupted using an ultrasonic homogenizer under the following conditions: Power: 20 W, rest: 3 sec, work: 3 sec, time: 10 min. The disrupted cells were centrifuged at 13000 rpm for 1 hour, and the supernatant and precipitated material were separated.

[0155] ScFv was expressed in an insoluble form, and pellet washing was performed to proceed with refolding. The pellet was washed twice by homogenizing with a homogenizer using 50 mM Tris-HCl pH 7.4, 150 mM NaCl buffer, and centrifuging at 13,000 rpm for 1 hour. The remaining E. coli-derived substances in the pellet were removed using 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 M urea, 0.5% Triton X-100 buffer, and washing was repeated three times with 50 mM Tris-HCl pH 7.4, 150 mM NaCl buffer. The inclusion bodies were resuspended in 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 8 M urea, 10 mM DTT buffer and reacted for approximately 30 minutes to produce an unfolded form of ScFv, which was then separated from the precipitate by centrifugation at 13,000 rpm for 1 hour.

[0156] The ScFv antibody was refolded by removing urea through step dialysis. The dialysis buffer was based on 50 mM Tris-HCl pH 7.4, 150 mM NaCl, and the urea concentration was decreased by half. In the 4-2-1M urea concentration range where most of the structure was formed, 0.1M L-arginine and 10% glycerol were added to suppress aggregation formation and refolding was performed. The refolded scFv antibody was separated and purified using HisTrap and Capo L columns.

[0157] The separation and purification were carried out in the following order. Purification was performed using the AKTA Purifier (GE Healthcare) system, and a 5ml HisTrap packing column was used. After equilibration by flowing 50mM Tris, 500mM NaCl, 10mM imidazole pH 7.4 buffer in a column volume 10 times the volume of the HisTrap column, the ScFv antibody sample was flowed through the HisTrap column at a flow rate of 3ml / min to bind to the resin in the column. After flowing 50mM Tris, 400mM NaCl, 10mM imidazole pH 7.4 buffer in a column volume approximately 10 times the volume of the column to remove non-specific binding substances present on the resin, 50mM Tris, 150mM NaCl, 400mM imidazole pH 7.4 buffer was flowed according to a concentration gradient to elute the scFv antibody. The eluted antibody sample was subjected to further purification using a 5 ml Capto L column. After equilibrating the Capto L column with 50 mM Tris, 150 mM NaCl pH 7.4 buffer, the sample was passed through the Capto L column at a flow rate of 3 ml / min to bind to the resin in the column. Non-specific binding substances were removed by passing PBS buffer for a column volume approximately 10 times the column volume. Non-specific binding substances that could not be removed by PBS buffer were removed by passing 50 mM Mes, 400 mM NaCl, 0.2% Tween 20 pH 5.5 buffer for 10 CV. The scFv antibody was eluted by passing 0.1 M Glycine, 50 mM NaCl pH 2.5 buffer for a column volume approximately 10 times the column volume. The pH of the eluted sample was neutralized with 1 M Tris pH 7.4 buffer. Figures 5a to 5g show the results of SDS-PAGE of the protein obtained after final purification. As a result, a highly pure ScFv antibody was obtained.

[0158] The specific sequence of the anti-Ang2 antibody with improved physical properties is as follows:

[0159] [Table 3] TIFF0007669062000006.tif236170

[0160] Example 4. Optimized ScFv enrichment of anti-Ang2 antibodies

[0161] For the analysis of the highest concentration where no aggregation phenomenon was observed, the samples were concentrated using centrifugation. The purified anti-Ang2 antibody was dialyzed against PBS and formulation buffer (10 mM sodium phosphate, 40 mM NaCl, 0.03% polysorbate, 5% sucrose pH 6.2) containing the formulation composition used in the commercial product to exchange the buffer. 10 ml of PBS or formulation buffer was placed in a Viva Spin Turbo 5,000 MWCO PEG tube (Sartorius) and equilibrated by centrifugation at 3400 g for 10 minutes. 10 ml of the buffer-exchanged sample was placed in a tube and centrifuged at 3400 g and 4°C for 10 minutes to concentrate. The absorbance was measured using NanoDrop (Thermo) to determine the concentration (Table 4).

[0162] [Table 4]

[0163] Example 5. Binding specificity analysis of optimized anti-Ang2 ScFv antibodies

[0164] The binding specificity was analyzed using the Octet system (Pall Fortebio LLC.US) to measure the binding constant.

[0165] The binding strength of the purified ScFv antibody to human Ang2 and mouse Ang2 was measured using an Octet system (Fortebio Inc. US). The AR2G biosensor was hydrated for 20 minutes. The AR2G biosensor was activated using a solution of 90% triple distilled water with 5% s-NHS and 5% EDC. Anti-Ang2 antibody was immobilized on the AR2G sensor at a concentration of 1 μg / ml. Quenching was performed with 1 M ethanolamine. After equilibration with PBS, the binding kinetics was measured for human Ang2 at concentrations of 50, 40, 30, and 20 nM, and the binding rate constant (k a ), dissociation rate constant (k dis ) and binding constant (K D ) was calculated (Table 5).

[0166] [Table 5]

[0167] Example 6: Thermal stability analysis of anti-Ang2 scFv antibodies

[0168] To analyze the thermal stability of anti-Ang2 scFv antibody, Tm was measured using RT-PCR. The analysis sample was prepared with 5 μl of Protein Thermal Shift Buffer (Thermo Fisher), 12.5 μl of anti-Ang2 scFv antibody (1 mg / ml in PBS pH 7.4 buffer), and 2.5 μl of 8X Protein Thermal Shift Dye, allowing two replicate experiments. For Tm analysis, the temperature was increased from 25°C to 99°C at a rate of 1.6°C / s using the Melt Curve Experiment Method built into the Quantastudio 5 Thermocycler (Thermo Fisher), and the fluorescence intensity (absorbance a (580±10 nm) - absorbance b (623±14 nm)) was measured every 0.05°C / s, and the Tm value was calculated using Protein Thermal Shift Software (Thermo Fisher). The Tm B value of the anti-Ang2 scFv antibody calculated using the Boltzmann equation was 77.31°C, which was an increase of more than 7°C compared to before the technical modification, indicating that the thermal stability was greatly improved by the technical modification (Figure 6).

[0169] Example 7: Evaluation of the anti-angiogenic efficacy of anti-Ang2 scFv antibodies using a mouse CNV model

[0170] To confirm whether the anti-Ang2 scFv antibody has an inhibitory effect on neovascularization, a pharmacological study was performed in a laser-induced choroidal neovascularization mouse model. The efficacy was tested using the commercial drug aflibercept as a control. After general anesthesia of the mice with ketamine, additional local anesthesia was administered by instilling an anesthetic eye drop into the eyeball, and mydriasis was induced by instilling a mydriatic. After placing the mice on the stage, laser burn was induced using Micron-IV under CNV induction conditions (wavelength 532 nm, diameter 50 μm, duration 80 mS, power level 200 mW) to destroy Bruch's membrane. Lesions in which no bubbling was observed during the laser burn induction process were classified as unsuccessful laser burns and were excluded from the result analysis and statistical processing process based on the modified exclusion criteria proposed by Gong Y. et al.

[0171] To confirm the induction of CNV and the inhibitory effect of drugs on angiogenesis, mice were anesthetized with ketamine 10 days after CNV induction and intraperitoneally injected with a fluorescent contrast agent. Anesthesia eye drops were applied to the eyeball to provide additional local anesthesia, and mydriasis was induced by applying a mydriatic. The mouse was placed on the stage and the fundus was imaged with a Micron-IV imaging camera. Lubricant gel was applied to the eyeball and the OCT lens was placed in contact with the mouse cornea. After FFA / OCT imaging, a single drop of antibiotic eye drops was applied to the mouse eyeball. Analysis of FFA and OCT images was performed using the Image-J program.

[0172] Electroretinogram (ERG) tests were performed to confirm the optic nerve recovery effect. Mice were dark-adapted in a dark room 12 hours before ERG evaluation. On the day of evaluation (11 days after CNV induction), general anesthesia was administered with Rumpun® and Ketamine®, and then Alcaine® was instilled into the eyeball to induce additional local anesthesia, and mydriasis was induced by instilling a mydriatic. The mouse was placed on the ERG stage, and the ERG probes were placed in contact with the tail, head, and cornea, respectively. ERG was measured using a single flash stimulus (0.9 log cds / m 2 The change in electroretinogram (ERG) was measured in response to a 10 response / intensity (10 responses / intensity). After the ERG assessment was completed, a single drop of Tobrex was instilled into the mouse eye. ERG analysis was performed using the program "LabScribeERG (iWorx DataAcquisition Software)".

[0173] Aflibercept was diluted with sterile PBS and administered once at a volume of 20 μg / μl / eye, and anti-Ang2 scFv antibody was administered once at volumes of 5 μg / μl / eye, 10 μg / μl / eye, and 20 μg / μl / eye via intravitreal injection (IVT) on the day after CNV induction. Ten days after CNV induction, retinal image evaluation was performed using fundus fluorescein angiography (FFA) and optical coherence tomography (OCT), and the size and cross-sectional area of ​​the CNV lesion were measured and compared. In addition, on the 11th day after CNV induction, a single flash (0.9 log cds / m) was recorded by nocturnal (scotopic) electroretinogram (ERG). 2The changes in the electroretinograms in response to stimuli were compared and evaluated as the amplitude from A-wave to B-wave. As a result, the size of the CNV lesions measured by FFA was statistically significantly reduced in the aflibercept-treated group (P<0.01) and the anti-Ang2 scFv antibody-treated groups at 10 μg / μl / eye and 20 μg / μl / eye compared to the vehicle-treated group (P<0.05, respectively) (Fig. 7a). The volume of the CNV lesions measured by OCT was also statistically significantly reduced in the anti-Ang2 scFv antibody-treated groups at 10 μg / μl / eye and 20 μg / μl / eye (P<0.01 and P<0.001, respectively) (Fig. 7b). When the electroretinograms on ERG were compared with the vehicle-treated group, it was confirmed that the electroretinograms were significantly increased in all of the aflibercept-treated and anti-Ang2 scFv antibody-treated groups (G3, G4, and G5) compared with the CNV control group, G1 (P<0.0001, P<0.0001, P<0.0001, and P<0.01, respectively) (Figure 7c). [Industrial Applicability]

[0174] The antibody or fragment thereof according to the present invention may contain mutations in the framework region to improve solubility and enable concentration at high concentrations, thereby improving antibody productivity.

[0175] Although the specific parts of the present invention have been described in detail above, it is obvious to those skilled in the art that such specific techniques are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents. [Sequence List Free Text]

[0176] Electronic file attached.

Claims

1. A modified antibody or antigen-binding fragment obtained by modifying an anti-Ang2 antibody, the modified antibody or antigen-binding fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO:34 and a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO:32, Binds to Ang2 (Angiopoietin-2), an amino acid sequence in which valine (V) at position 13 in the heavy chain variable region in the amino acid sequence represented by SEQ ID NO: 34 is substituted with serine (S); an amino acid sequence in which asparagine (N) at position 42 in the heavy chain variable region in the amino acid sequence represented by SEQ ID NO: 34 is substituted with threonine (T); and an amino acid sequence in which asparagine (N) at position 94 in the light chain variable region in the amino acid sequence represented by SEQ ID NO: 32 is substituted with serine (S); wherein the amino acid substitution positions are based on the AHO numbering system; Modified antibodies or antigen-binding fragments.

2. A modified antibody or antigen-binding fragment obtained by modifying an anti-Ang2 antibody, the modified antibody or antigen-binding fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO:34 and a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO:32, Binds to Ang2 (Angiopoietin-2), In the heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 34, valine at position 13 and / or asparagine at position 42 based on the AHO numbering system are substituted, The heavy chain variable region with the amino acid substitution is QVQLVESGGGLX. １ KPGGSLRLSCAAS (the above X １ is S) and / or MX ２ WVRQAPGKGLEWVSS (the above X ２ A framework region having the sequence: Modified antibodies or antigen-binding fragments.

3. A modified antibody or antigen-binding fragment obtained by modifying an anti-Ang2 antibody, the modified antibody or antigen-binding fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO:34 and a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO:32, Binds to Ang2 (Angiopoietin-2), In the light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 32, an asparagine at position 94 based on the AHO numbering system is substituted, The light chain variable region with the amino acid substitution is NLQSGVSSQFSGSGSGTDFTLTIX. ３ SLQPEDSATYYC (the above X ３ S Modified antibodies or antigen-binding fragments.

4. A modified antibody or antigen-binding fragment obtained by modifying an anti-Ang2 antibody, the modified antibody or antigen-binding fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO:34 and a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO:32, Binds to Ang2 (Angiopoietin-2), In the heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 34, one or more amino acids selected from the group consisting of valine at position 13, asparagine at position 42, and in the light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 32, asparagine at position 94, are substituted, wherein the positions are based on the AHO numbering system: The variable regions with amino acid substitutions are as follows: QVQLVESGGGLX １ KPGGSLRLSCAAS (the above X １ is S); M.X. ２ WVRQAPGKGLEWVSS (the above X ２ is T); and NLQSGVSSQFSGSGSGTDFTLTIX ３ SLQPEDSATYYC (the above X ３ is S), comprising one or more framework regions selected from the group consisting of: Modified antibodies or antigen-binding fragments.

5. A modified antibody or antigen-binding fragment obtained by modifying an anti-Ang2 antibody, the modified antibody or antigen-binding fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO:34 and a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO:32, Binds to Ang2 (Angiopoietin-2), In the heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 34, one or more amino acids selected from the group consisting of valine at position 13, asparagine at position 42, and in the light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 32, asparagine at position 94, are substituted, wherein the positions are based on the AHO numbering system: A modified antibody or antigen-binding fragment, wherein the heavy chain variable region having an amino acid substitution comprises one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 31, 33, and 36.

6. A modified antibody or antigen-binding fragment obtained by modifying an anti-Ang2 antibody, the modified antibody or antigen-binding fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO:34 and a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO:32, Binds to Ang2 (Angiopoietin-2), In the heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 34, one or more amino acids selected from the group consisting of valine at position 13, asparagine at position 42, and in the light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 32, asparagine at position 94, are substituted, wherein the positions are based on the AHO numbering system: A modified antibody or antigen-binding fragment, wherein the light chain variable region having an amino acid substitution comprises the amino acid sequence set forth in SEQ ID NO:

35.

7. A modified antibody or antigen-binding fragment obtained by modifying an anti-Ang2 antibody, the modified antibody or antigen-binding fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO:34 and a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO:32, Binds to Ang2 (Angiopoietin-2), In the heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 34, one or more amino acids selected from the group consisting of valine at position 13, asparagine at position 42, and in the light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 32, asparagine at position 94, are substituted, wherein the positions are based on the AHO numbering system: A heavy chain variable region set forth in SEQ ID NO:31 and a light chain variable region set forth in SEQ ID NO:32; A heavy chain variable region set forth in SEQ ID NO: 33 and a light chain variable region set forth in SEQ ID NO: 32; A heavy chain variable region set forth in SEQ ID NO:36 and a light chain variable region set forth in SEQ ID NO:32; A heavy chain variable region set forth in SEQ ID NO:31 and a light chain variable region set forth in SEQ ID NO:35; A heavy chain variable region set forth in SEQ ID NO: 33 and a light chain variable region set forth in SEQ ID NO: 35; A heavy chain variable region set forth in SEQ ID NO: 34 and a light chain variable region set forth in SEQ ID NO: 35; or A modified antibody or antigen-binding fragment comprising: a heavy chain variable region set forth in SEQ ID NO:36 and a light chain variable region set forth in SEQ ID NO:

35.

8. A heavy chain variable region comprising heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 consisting of the amino acid sequences represented by SEQ ID NOs: 13, 14, and 43, respectively; and A light chain variable region comprising a light chain CDR1, a light chain CDR2, and a light chain CDR3 consisting of the amino acid sequences represented by SEQ ID NOs: 16, 17, and 18, respectively; The modified antibody or antigen-binding fragment of any one of claims 1 to 7, comprising:

9. A nucleic acid encoding the modified antibody or antigen-binding fragment of any one of claims 1 to 7.

10. An expression vector comprising the nucleic acid of claim 9.

11. A cell transformed with the expression vector according to claim 10. (a) culturing the cell of claim 11; and (b) recovering the modified antibody or antigen-binding fragment from the cultured cells; A method for producing a modified antibody or antigen-binding fragment comprising:

13. A nucleic acid encoding the modified antibody or antigen-binding fragment of claim 8.

14. An expression vector comprising the nucleic acid described in claim 13.

15. A cell transformed with the expression vector described in claim 14. (a) culturing the cell of claim 15; and (b) recovering the modified antibody or antigen-binding fragment from the cultured cells; A method for producing a modified antibody or antigen-binding fragment comprising:

Images